MedTrace Logo

Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore

NCT02425098 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 351

Last updated 2019-08-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the post-vaccination neutralizing antibody response against each dengue serotype by vaccine group.

Conditions

  • Dengue Fever

Interventions

BIOLOGICAL

Takeda's Tetravalent Dengue Vaccine Candidate (TDV)

TDV subcutaneous injection

BIOLOGICAL

Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV)

High-dose TDV subcutaneous injection

Sponsors & Collaborators

Principal Investigators

  • Medical Director Clinical Science · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-06-03
Primary Completion
2017-09-18
Completion
2017-09-18

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02425098 on ClinicalTrials.gov